8 September 2021 - Nivolumab scores only its second final rejection to date from NICE.

Nivolumab, when used in combination with ipilimumab and two cycles of platinum-doublet chemotherapy, is not recommended for untreated adults with metastatic non-small-cell lung cancer  whose tumours have no epidermal growth factor receptor or anaplastic lymphoma kinase mutations.

Read NICE technology appraisal guidance